Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization
Brian D. Griffith(University of Michigan), Timothy L. Frankel(National Institutes of Health)
Cited by 1
Related Papers
Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase
|The Journal of Immunology|2010|82
A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions
|International Journal of Molecular Sciences|2024|13